nodes	percent_of_prediction	percent_of_DWPC	metapath
Temozolomide—Alkylating Activity—Melphalan—peripheral nervous system neoplasm	0.282	0.556	CiPCiCtD
Temozolomide—Alkylating Activity—Dacarbazine—peripheral nervous system neoplasm	0.226	0.444	CiPCiCtD
Temozolomide—malignant glioma—peripheral nervous system neoplasm	0.209	0.536	CtDrD
Temozolomide—brain cancer—peripheral nervous system neoplasm	0.105	0.269	CtDrD
Temozolomide—skin cancer—peripheral nervous system neoplasm	0.0757	0.195	CtDrD
Temozolomide—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.011	0.332	CbGbCtD
Temozolomide—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0102	0.308	CbGbCtD
Temozolomide—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.0047	0.142	CbGbCtD
Temozolomide—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00431	0.13	CbGbCtD
Temozolomide—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00294	0.0885	CbGbCtD
Temozolomide—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	2.4e-05	0.000345	CcSEcCtD
Temozolomide—Pancytopenia—Epirubicin—peripheral nervous system neoplasm	2.38e-05	0.000343	CcSEcCtD
Temozolomide—Pain—Cisplatin—peripheral nervous system neoplasm	2.37e-05	0.000342	CcSEcCtD
Temozolomide—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	2.37e-05	0.000341	CcSEcCtD
Temozolomide—Muscular weakness—Doxorubicin—peripheral nervous system neoplasm	2.37e-05	0.000341	CcSEcCtD
Temozolomide—Dysuria—Epirubicin—peripheral nervous system neoplasm	2.34e-05	0.000337	CcSEcCtD
Temozolomide—Neutropenia—Epirubicin—peripheral nervous system neoplasm	2.34e-05	0.000337	CcSEcCtD
Temozolomide—Asthenia—Alitretinoin—peripheral nervous system neoplasm	2.34e-05	0.000337	CcSEcCtD
Temozolomide—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	2.34e-05	0.000336	CcSEcCtD
Temozolomide—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	2.33e-05	0.000335	CcSEcCtD
Temozolomide—Dysphagia—Doxorubicin—peripheral nervous system neoplasm	2.32e-05	0.000334	CcSEcCtD
Temozolomide—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	2.32e-05	0.000333	CcSEcCtD
Temozolomide—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	2.31e-05	0.000333	CcSEcCtD
Temozolomide—Pruritus—Alitretinoin—peripheral nervous system neoplasm	2.31e-05	0.000332	CcSEcCtD
Temozolomide—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	2.29e-05	0.000329	CcSEcCtD
Temozolomide—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	2.29e-05	0.000329	CcSEcCtD
Temozolomide—Paraesthesia—Etoposide—peripheral nervous system neoplasm	2.28e-05	0.000329	CcSEcCtD
Temozolomide—Weight increased—Epirubicin—peripheral nervous system neoplasm	2.28e-05	0.000328	CcSEcCtD
Temozolomide—Weight decreased—Epirubicin—peripheral nervous system neoplasm	2.27e-05	0.000327	CcSEcCtD
Temozolomide—Dyspnoea—Etoposide—peripheral nervous system neoplasm	2.27e-05	0.000326	CcSEcCtD
Temozolomide—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	2.26e-05	0.000326	CcSEcCtD
Temozolomide—Somnolence—Etoposide—peripheral nervous system neoplasm	2.26e-05	0.000325	CcSEcCtD
Temozolomide—Asthenia—Vincristine—peripheral nervous system neoplasm	2.25e-05	0.000324	CcSEcCtD
Temozolomide—Pneumonia—Epirubicin—peripheral nervous system neoplasm	2.25e-05	0.000324	CcSEcCtD
Temozolomide—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	2.24e-05	0.000322	CcSEcCtD
Temozolomide—Infestation—Epirubicin—peripheral nervous system neoplasm	2.24e-05	0.000322	CcSEcCtD
Temozolomide—Vomiting—Dactinomycin—peripheral nervous system neoplasm	2.23e-05	0.000322	CcSEcCtD
Temozolomide—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	2.23e-05	0.000321	CcSEcCtD
Temozolomide—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	2.23e-05	0.000321	CcSEcCtD
Temozolomide—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	2.22e-05	0.000319	CcSEcCtD
Temozolomide—Rash—Dactinomycin—peripheral nervous system neoplasm	2.22e-05	0.000319	CcSEcCtD
Temozolomide—Decreased appetite—Etoposide—peripheral nervous system neoplasm	2.21e-05	0.000318	CcSEcCtD
Temozolomide—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	2.2e-05	0.000317	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	2.2e-05	0.000316	CcSEcCtD
Temozolomide—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	2.19e-05	0.000316	CcSEcCtD
Temozolomide—Fatigue—Etoposide—peripheral nervous system neoplasm	2.19e-05	0.000316	CcSEcCtD
Temozolomide—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	2.19e-05	0.000315	CcSEcCtD
Temozolomide—Stomatitis—Epirubicin—peripheral nervous system neoplasm	2.18e-05	0.000314	CcSEcCtD
Temozolomide—Pain—Etoposide—peripheral nervous system neoplasm	2.18e-05	0.000313	CcSEcCtD
Temozolomide—Constipation—Etoposide—peripheral nervous system neoplasm	2.18e-05	0.000313	CcSEcCtD
Temozolomide—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	2.17e-05	0.000313	CcSEcCtD
Temozolomide—Dysuria—Doxorubicin—peripheral nervous system neoplasm	2.17e-05	0.000312	CcSEcCtD
Temozolomide—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	2.17e-05	0.000312	CcSEcCtD
Temozolomide—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	2.16e-05	0.00031	CcSEcCtD
Temozolomide—Dizziness—Alitretinoin—peripheral nervous system neoplasm	2.15e-05	0.00031	CcSEcCtD
Temozolomide—Diarrhoea—Vincristine—peripheral nervous system neoplasm	2.15e-05	0.000309	CcSEcCtD
Temozolomide—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	2.14e-05	0.000308	CcSEcCtD
Temozolomide—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	2.12e-05	0.000305	CcSEcCtD
Temozolomide—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	2.11e-05	0.000304	CcSEcCtD
Temozolomide—Weight increased—Doxorubicin—peripheral nervous system neoplasm	2.11e-05	0.000304	CcSEcCtD
Temozolomide—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	2.1e-05	0.000302	CcSEcCtD
Temozolomide—Sinusitis—Epirubicin—peripheral nervous system neoplasm	2.1e-05	0.000302	CcSEcCtD
Temozolomide—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	2.1e-05	0.000302	CcSEcCtD
Temozolomide—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	2.09e-05	0.000301	CcSEcCtD
Temozolomide—Nausea—Dactinomycin—peripheral nervous system neoplasm	2.09e-05	0.0003	CcSEcCtD
Temozolomide—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	2.08e-05	0.000299	CcSEcCtD
Temozolomide—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	2.08e-05	0.000299	CcSEcCtD
Temozolomide—Dizziness—Vincristine—peripheral nervous system neoplasm	2.08e-05	0.000299	CcSEcCtD
Temozolomide—Vomiting—Alitretinoin—peripheral nervous system neoplasm	2.07e-05	0.000298	CcSEcCtD
Temozolomide—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	2.07e-05	0.000298	CcSEcCtD
Temozolomide—Infestation—Doxorubicin—peripheral nervous system neoplasm	2.07e-05	0.000298	CcSEcCtD
Temozolomide—Rash—Alitretinoin—peripheral nervous system neoplasm	2.05e-05	0.000296	CcSEcCtD
Temozolomide—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	2.05e-05	0.000295	CcSEcCtD
Temozolomide—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	2.05e-05	0.000295	CcSEcCtD
Temozolomide—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	2.05e-05	0.000294	CcSEcCtD
Temozolomide—Headache—Alitretinoin—peripheral nervous system neoplasm	2.04e-05	0.000294	CcSEcCtD
Temozolomide—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	2.03e-05	0.000292	CcSEcCtD
Temozolomide—Urticaria—Etoposide—peripheral nervous system neoplasm	2.02e-05	0.000291	CcSEcCtD
Temozolomide—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	2.02e-05	0.00029	CcSEcCtD
Temozolomide—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	2.02e-05	0.00029	CcSEcCtD
Temozolomide—Abdominal pain—Etoposide—peripheral nervous system neoplasm	2.01e-05	0.000289	CcSEcCtD
Temozolomide—Body temperature increased—Etoposide—peripheral nervous system neoplasm	2.01e-05	0.000289	CcSEcCtD
Temozolomide—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	2.01e-05	0.000289	CcSEcCtD
Temozolomide—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	2.01e-05	0.000289	CcSEcCtD
Temozolomide—Hepatitis—Epirubicin—peripheral nervous system neoplasm	2.01e-05	0.000289	CcSEcCtD
Temozolomide—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	2e-05	0.000287	CcSEcCtD
Temozolomide—Vomiting—Vincristine—peripheral nervous system neoplasm	2e-05	0.000287	CcSEcCtD
Temozolomide—Asthenia—Cisplatin—peripheral nervous system neoplasm	1.99e-05	0.000287	CcSEcCtD
Temozolomide—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	1.99e-05	0.000287	CcSEcCtD
Temozolomide—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	1.98e-05	0.000285	CcSEcCtD
Temozolomide—Rash—Vincristine—peripheral nervous system neoplasm	1.98e-05	0.000285	CcSEcCtD
Temozolomide—Dermatitis—Vincristine—peripheral nervous system neoplasm	1.98e-05	0.000285	CcSEcCtD
Temozolomide—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	1.98e-05	0.000285	CcSEcCtD
Temozolomide—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	1.97e-05	0.000284	CcSEcCtD
Temozolomide—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	1.97e-05	0.000283	CcSEcCtD
Temozolomide—Headache—Vincristine—peripheral nervous system neoplasm	1.97e-05	0.000283	CcSEcCtD
Temozolomide—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	1.96e-05	0.000282	CcSEcCtD
Temozolomide—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	1.94e-05	0.000279	CcSEcCtD
Temozolomide—Nausea—Alitretinoin—peripheral nervous system neoplasm	1.94e-05	0.000279	CcSEcCtD
Temozolomide—Visual impairment—Epirubicin—peripheral nervous system neoplasm	1.93e-05	0.000278	CcSEcCtD
Temozolomide—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	1.9e-05	0.000273	CcSEcCtD
Temozolomide—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	1.9e-05	0.000273	CcSEcCtD
Temozolomide—Eye disorder—Epirubicin—peripheral nervous system neoplasm	1.88e-05	0.00027	CcSEcCtD
Temozolomide—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	1.87e-05	0.00027	CcSEcCtD
Temozolomide—Tinnitus—Epirubicin—peripheral nervous system neoplasm	1.87e-05	0.000269	CcSEcCtD
Temozolomide—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	1.87e-05	0.000269	CcSEcCtD
Temozolomide—Nausea—Vincristine—peripheral nervous system neoplasm	1.87e-05	0.000268	CcSEcCtD
Temozolomide—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	1.86e-05	0.000268	CcSEcCtD
Temozolomide—Flushing—Epirubicin—peripheral nervous system neoplasm	1.86e-05	0.000268	CcSEcCtD
Temozolomide—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	1.86e-05	0.000267	CcSEcCtD
Temozolomide—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	1.86e-05	0.000267	CcSEcCtD
Temozolomide—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	1.85e-05	0.000266	CcSEcCtD
Temozolomide—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	1.84e-05	0.000265	CcSEcCtD
Temozolomide—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	1.83e-05	0.000264	CcSEcCtD
Temozolomide—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	1.83e-05	0.000263	CcSEcCtD
Temozolomide—Asthenia—Etoposide—peripheral nervous system neoplasm	1.82e-05	0.000263	CcSEcCtD
Temozolomide—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	1.82e-05	0.000263	CcSEcCtD
Temozolomide—Angiopathy—Epirubicin—peripheral nervous system neoplasm	1.82e-05	0.000262	CcSEcCtD
Temozolomide—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	1.82e-05	0.000262	CcSEcCtD
Temozolomide—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	1.81e-05	0.000261	CcSEcCtD
Temozolomide—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	1.81e-05	0.00026	CcSEcCtD
Temozolomide—Chills—Epirubicin—peripheral nervous system neoplasm	1.8e-05	0.000259	CcSEcCtD
Temozolomide—Pruritus—Etoposide—peripheral nervous system neoplasm	1.8e-05	0.000259	CcSEcCtD
Temozolomide—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	1.79e-05	0.000258	CcSEcCtD
Temozolomide—Alopecia—Epirubicin—peripheral nervous system neoplasm	1.77e-05	0.000255	CcSEcCtD
Temozolomide—Vomiting—Cisplatin—peripheral nervous system neoplasm	1.77e-05	0.000254	CcSEcCtD
Temozolomide—Mental disorder—Epirubicin—peripheral nervous system neoplasm	1.76e-05	0.000253	CcSEcCtD
Temozolomide—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	1.76e-05	0.000253	CcSEcCtD
Temozolomide—Rash—Cisplatin—peripheral nervous system neoplasm	1.75e-05	0.000252	CcSEcCtD
Temozolomide—Dermatitis—Cisplatin—peripheral nervous system neoplasm	1.75e-05	0.000252	CcSEcCtD
Temozolomide—Erythema—Epirubicin—peripheral nervous system neoplasm	1.75e-05	0.000251	CcSEcCtD
Temozolomide—Malnutrition—Epirubicin—peripheral nervous system neoplasm	1.75e-05	0.000251	CcSEcCtD
Temozolomide—Diarrhoea—Etoposide—peripheral nervous system neoplasm	1.74e-05	0.000251	CcSEcCtD
Temozolomide—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	1.74e-05	0.00025	CcSEcCtD
Temozolomide—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	1.73e-05	0.000249	CcSEcCtD
Temozolomide—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	1.72e-05	0.000248	CcSEcCtD
Temozolomide—Flushing—Doxorubicin—peripheral nervous system neoplasm	1.72e-05	0.000248	CcSEcCtD
Temozolomide—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	1.71e-05	0.000246	CcSEcCtD
Temozolomide—Back pain—Epirubicin—peripheral nervous system neoplasm	1.69e-05	0.000243	CcSEcCtD
Temozolomide—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	1.68e-05	0.000243	CcSEcCtD
Temozolomide—Dizziness—Etoposide—peripheral nervous system neoplasm	1.68e-05	0.000242	CcSEcCtD
Temozolomide—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	1.68e-05	0.000241	CcSEcCtD
Temozolomide—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	1.67e-05	0.000241	CcSEcCtD
Temozolomide—Chills—Doxorubicin—peripheral nervous system neoplasm	1.67e-05	0.00024	CcSEcCtD
Temozolomide—Nausea—Cisplatin—peripheral nervous system neoplasm	1.65e-05	0.000237	CcSEcCtD
Temozolomide—Vision blurred—Epirubicin—peripheral nervous system neoplasm	1.65e-05	0.000237	CcSEcCtD
Temozolomide—Alopecia—Doxorubicin—peripheral nervous system neoplasm	1.64e-05	0.000236	CcSEcCtD
Temozolomide—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	1.63e-05	0.000234	CcSEcCtD
Temozolomide—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	1.62e-05	0.000233	CcSEcCtD
Temozolomide—Vomiting—Etoposide—peripheral nervous system neoplasm	1.62e-05	0.000233	CcSEcCtD
Temozolomide—Erythema—Doxorubicin—peripheral nervous system neoplasm	1.62e-05	0.000233	CcSEcCtD
Temozolomide—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	1.62e-05	0.000233	CcSEcCtD
Temozolomide—Anaemia—Epirubicin—peripheral nervous system neoplasm	1.61e-05	0.000232	CcSEcCtD
Temozolomide—Agitation—Epirubicin—peripheral nervous system neoplasm	1.61e-05	0.000231	CcSEcCtD
Temozolomide—Rash—Etoposide—peripheral nervous system neoplasm	1.6e-05	0.000231	CcSEcCtD
Temozolomide—Dermatitis—Etoposide—peripheral nervous system neoplasm	1.6e-05	0.000231	CcSEcCtD
Temozolomide—Headache—Etoposide—peripheral nervous system neoplasm	1.59e-05	0.000229	CcSEcCtD
Temozolomide—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	1.58e-05	0.000228	CcSEcCtD
Temozolomide—Malaise—Epirubicin—peripheral nervous system neoplasm	1.58e-05	0.000227	CcSEcCtD
Temozolomide—Vertigo—Epirubicin—peripheral nervous system neoplasm	1.57e-05	0.000226	CcSEcCtD
Temozolomide—Leukopenia—Epirubicin—peripheral nervous system neoplasm	1.56e-05	0.000225	CcSEcCtD
Temozolomide—Back pain—Doxorubicin—peripheral nervous system neoplasm	1.56e-05	0.000225	CcSEcCtD
Temozolomide—Palpitations—Epirubicin—peripheral nervous system neoplasm	1.54e-05	0.000222	CcSEcCtD
Temozolomide—Cough—Epirubicin—peripheral nervous system neoplasm	1.52e-05	0.000219	CcSEcCtD
Temozolomide—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	1.52e-05	0.000219	CcSEcCtD
Temozolomide—Convulsion—Epirubicin—peripheral nervous system neoplasm	1.51e-05	0.000218	CcSEcCtD
Temozolomide—Nausea—Etoposide—peripheral nervous system neoplasm	1.51e-05	0.000217	CcSEcCtD
Temozolomide—Hypertension—Epirubicin—peripheral nervous system neoplasm	1.51e-05	0.000217	CcSEcCtD
Temozolomide—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	1.5e-05	0.000216	CcSEcCtD
Temozolomide—Anaemia—Doxorubicin—peripheral nervous system neoplasm	1.49e-05	0.000215	CcSEcCtD
Temozolomide—Myalgia—Epirubicin—peripheral nervous system neoplasm	1.49e-05	0.000214	CcSEcCtD
Temozolomide—Arthralgia—Epirubicin—peripheral nervous system neoplasm	1.49e-05	0.000214	CcSEcCtD
Temozolomide—Agitation—Doxorubicin—peripheral nervous system neoplasm	1.49e-05	0.000214	CcSEcCtD
Temozolomide—Anxiety—Epirubicin—peripheral nervous system neoplasm	1.48e-05	0.000213	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	1.48e-05	0.000213	CcSEcCtD
Temozolomide—Discomfort—Epirubicin—peripheral nervous system neoplasm	1.47e-05	0.000212	CcSEcCtD
Temozolomide—Malaise—Doxorubicin—peripheral nervous system neoplasm	1.46e-05	0.00021	CcSEcCtD
Temozolomide—Dry mouth—Epirubicin—peripheral nervous system neoplasm	1.45e-05	0.000209	CcSEcCtD
Temozolomide—Vertigo—Doxorubicin—peripheral nervous system neoplasm	1.45e-05	0.000209	CcSEcCtD
Temozolomide—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	1.45e-05	0.000208	CcSEcCtD
Temozolomide—Confusional state—Epirubicin—peripheral nervous system neoplasm	1.44e-05	0.000207	CcSEcCtD
Temozolomide—Palpitations—Doxorubicin—peripheral nervous system neoplasm	1.43e-05	0.000206	CcSEcCtD
Temozolomide—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	1.43e-05	0.000205	CcSEcCtD
Temozolomide—Oedema—Epirubicin—peripheral nervous system neoplasm	1.43e-05	0.000205	CcSEcCtD
Temozolomide—Infection—Epirubicin—peripheral nervous system neoplasm	1.42e-05	0.000204	CcSEcCtD
Temozolomide—Cough—Doxorubicin—peripheral nervous system neoplasm	1.41e-05	0.000203	CcSEcCtD
Temozolomide—Convulsion—Doxorubicin—peripheral nervous system neoplasm	1.4e-05	0.000202	CcSEcCtD
Temozolomide—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	1.4e-05	0.000201	CcSEcCtD
Temozolomide—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	1.4e-05	0.000201	CcSEcCtD
Temozolomide—Hypertension—Doxorubicin—peripheral nervous system neoplasm	1.4e-05	0.000201	CcSEcCtD
Temozolomide—Skin disorder—Epirubicin—peripheral nervous system neoplasm	1.38e-05	0.000199	CcSEcCtD
Temozolomide—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	1.38e-05	0.000198	CcSEcCtD
Temozolomide—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	1.38e-05	0.000198	CcSEcCtD
Temozolomide—Myalgia—Doxorubicin—peripheral nervous system neoplasm	1.38e-05	0.000198	CcSEcCtD
Temozolomide—Anxiety—Doxorubicin—peripheral nervous system neoplasm	1.37e-05	0.000197	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	1.37e-05	0.000197	CcSEcCtD
Temozolomide—Discomfort—Doxorubicin—peripheral nervous system neoplasm	1.36e-05	0.000196	CcSEcCtD
Temozolomide—Anorexia—Epirubicin—peripheral nervous system neoplasm	1.36e-05	0.000196	CcSEcCtD
Temozolomide—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	1.35e-05	0.000194	CcSEcCtD
Temozolomide—Confusional state—Doxorubicin—peripheral nervous system neoplasm	1.33e-05	0.000191	CcSEcCtD
Temozolomide—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	1.32e-05	0.00019	CcSEcCtD
Temozolomide—Oedema—Doxorubicin—peripheral nervous system neoplasm	1.32e-05	0.00019	CcSEcCtD
Temozolomide—Infection—Doxorubicin—peripheral nervous system neoplasm	1.31e-05	0.000189	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	1.3e-05	0.000187	CcSEcCtD
Temozolomide—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	1.29e-05	0.000186	CcSEcCtD
Temozolomide—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	1.29e-05	0.000186	CcSEcCtD
Temozolomide—Insomnia—Epirubicin—peripheral nervous system neoplasm	1.29e-05	0.000186	CcSEcCtD
Temozolomide—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	1.28e-05	0.000184	CcSEcCtD
Temozolomide—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	1.28e-05	0.000184	CcSEcCtD
Temozolomide—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	1.28e-05	0.000184	CcSEcCtD
Temozolomide—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	1.27e-05	0.000183	CcSEcCtD
Temozolomide—Somnolence—Epirubicin—peripheral nervous system neoplasm	1.27e-05	0.000182	CcSEcCtD
Temozolomide—Anorexia—Doxorubicin—peripheral nervous system neoplasm	1.26e-05	0.000181	CcSEcCtD
Temozolomide—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	1.26e-05	0.000181	CcSEcCtD
Temozolomide—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	1.24e-05	0.000178	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	1.23e-05	0.000177	CcSEcCtD
Temozolomide—Fatigue—Epirubicin—peripheral nervous system neoplasm	1.23e-05	0.000177	CcSEcCtD
Temozolomide—Pain—Epirubicin—peripheral nervous system neoplasm	1.22e-05	0.000176	CcSEcCtD
Temozolomide—Constipation—Epirubicin—peripheral nervous system neoplasm	1.22e-05	0.000176	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	1.2e-05	0.000173	CcSEcCtD
Temozolomide—Insomnia—Doxorubicin—peripheral nervous system neoplasm	1.19e-05	0.000172	CcSEcCtD
Temozolomide—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	1.18e-05	0.000171	CcSEcCtD
Temozolomide—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	1.18e-05	0.000169	CcSEcCtD
Temozolomide—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	1.17e-05	0.000169	CcSEcCtD
Temozolomide—Somnolence—Doxorubicin—peripheral nervous system neoplasm	1.17e-05	0.000169	CcSEcCtD
Temozolomide—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	1.17e-05	0.000168	CcSEcCtD
Temozolomide—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	1.16e-05	0.000167	CcSEcCtD
Temozolomide—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	1.15e-05	0.000165	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	1.14e-05	0.000164	CcSEcCtD
Temozolomide—Fatigue—Doxorubicin—peripheral nervous system neoplasm	1.14e-05	0.000164	CcSEcCtD
Temozolomide—Urticaria—Epirubicin—peripheral nervous system neoplasm	1.13e-05	0.000163	CcSEcCtD
Temozolomide—Pain—Doxorubicin—peripheral nervous system neoplasm	1.13e-05	0.000162	CcSEcCtD
Temozolomide—Constipation—Doxorubicin—peripheral nervous system neoplasm	1.13e-05	0.000162	CcSEcCtD
Temozolomide—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	1.13e-05	0.000162	CcSEcCtD
Temozolomide—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	1.13e-05	0.000162	CcSEcCtD
Temozolomide—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	1.09e-05	0.000156	CcSEcCtD
Temozolomide—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	1.08e-05	0.000155	CcSEcCtD
Temozolomide—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	1.05e-05	0.000151	CcSEcCtD
Temozolomide—Urticaria—Doxorubicin—peripheral nervous system neoplasm	1.05e-05	0.000151	CcSEcCtD
Temozolomide—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	1.04e-05	0.00015	CcSEcCtD
Temozolomide—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	1.04e-05	0.00015	CcSEcCtD
Temozolomide—Asthenia—Epirubicin—peripheral nervous system neoplasm	1.02e-05	0.000147	CcSEcCtD
Temozolomide—Pruritus—Epirubicin—peripheral nervous system neoplasm	1.01e-05	0.000145	CcSEcCtD
Temozolomide—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	9.76e-06	0.00014	CcSEcCtD
Temozolomide—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	9.72e-06	0.00014	CcSEcCtD
Temozolomide—Asthenia—Doxorubicin—peripheral nervous system neoplasm	9.47e-06	0.000136	CcSEcCtD
Temozolomide—Dizziness—Epirubicin—peripheral nervous system neoplasm	9.43e-06	0.000136	CcSEcCtD
Temozolomide—Pruritus—Doxorubicin—peripheral nervous system neoplasm	9.33e-06	0.000134	CcSEcCtD
Temozolomide—Vomiting—Epirubicin—peripheral nervous system neoplasm	9.07e-06	0.00013	CcSEcCtD
Temozolomide—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	9.03e-06	0.00013	CcSEcCtD
Temozolomide—Rash—Epirubicin—peripheral nervous system neoplasm	8.99e-06	0.000129	CcSEcCtD
Temozolomide—Dermatitis—Epirubicin—peripheral nervous system neoplasm	8.98e-06	0.000129	CcSEcCtD
Temozolomide—Headache—Epirubicin—peripheral nervous system neoplasm	8.93e-06	0.000129	CcSEcCtD
Temozolomide—Dizziness—Doxorubicin—peripheral nervous system neoplasm	8.72e-06	0.000126	CcSEcCtD
Temozolomide—Nausea—Epirubicin—peripheral nervous system neoplasm	8.47e-06	0.000122	CcSEcCtD
Temozolomide—Vomiting—Doxorubicin—peripheral nervous system neoplasm	8.39e-06	0.000121	CcSEcCtD
Temozolomide—Rash—Doxorubicin—peripheral nervous system neoplasm	8.32e-06	0.00012	CcSEcCtD
Temozolomide—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	8.31e-06	0.00012	CcSEcCtD
Temozolomide—Headache—Doxorubicin—peripheral nervous system neoplasm	8.26e-06	0.000119	CcSEcCtD
Temozolomide—Nausea—Doxorubicin—peripheral nervous system neoplasm	7.84e-06	0.000113	CcSEcCtD
